Immunex announced its new, $50 million, 50,000-sf Process Development Facility in Bothell, WA is now operational. The new center, where the company will test and refine drug-production methods, is adjacent to its existing clinical-manufacturing center.

Immunex is a publicly traded biopharmaceutical company focusing on drugs for the immune system. For the fiscal year ended December 31, revenues increased 59% to $861.8 million, while net income nearly quadrupled to $154.4 million.

In noontime trading Monday, shares were trading at $13.96 apiece, up 71 cents from Friday's close. The price is a little more than $3 over its 52-week low of $10.75 that occurred a few weeks ago on March 23, but well below its 52-week high of $67.12 achieved in July of 2000.